Acceleron Pharma (XLRN) Tops Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Tops Q2 EPS by 7c

Acceleron Reports Second Quarter 2021 Financial Results

August 5, 2021 4:01 PM EDT

- Highlighted ongoing and planned trials in rare pulmonary diseases and presented vision and strategy for long-term growth at June R&D Day -

- Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Thoracic Society (ATS) 2021 International Conference -

- Acceleron recognized approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL® (luspatercept-aamt) -

- First results from BEYOND Phase 2 trial of luspatercept in adult patients with non-transfusion-dependent... More